Company / Revenue
PALVELLA THERAPEUTICS, INC. Revenue History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$42.8M
FY2023
5-year range
$25.9M / $46.3M
FY2019-FY2023
Trend
+65.3%
vs FY2022
Sector context
#123 of 155
Health Care
What the data says
PALVELLA THERAPEUTICS, INC.'s revenue of $43M is lower than 79% of companies in the Health Care sector (FY2023). Revenue returned to growth in FY2023 after 2 years of decline, reaching $43M.
Based on SEC 10-K filings.
$43M in FY2023 with a 5-year CAGR of +11.1%.
Improved from $29M to $43M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -2.6%
- 5-Year CAGR
- +11.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 155This company $42.8M Sector average $4.5B
▼
-99.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +11.1%, indicating consistent growth.
- In FY2023, revenue increased 65.3% year-over-year.
- Ranks #123 out of 155 companies in the Health Care sector.
- Peak revenue was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score 1.15 (distress zone, below 1.8 threshold)
- Strong profit margin: 43.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | $42.8M | +65.3% |
| FY2022 | $25.9M | -11.7% |
| FY2021 | $29.3M | -36.6% |
| FY2020 | $46.3M | +0.0% |
| FY2019 | $46.3M | +83.1% |
| FY2018 | $25.3M | +333.5% |
| FY2017 | $5.8M | +0.0% |
| FY2016 | $5.8M | +98.9% |
| FY2015 | $2.9M | -45.4% |
As of FY2023 · SEC 10-K Annual Filings · Updated Jun 30, 2026